Biotechnology · South San Francisco, California, United States
$19.38
+2.76% (+$0.52)2026-05-26
Revenue$0
Net Income-$107.2M
EPS$-1.89
Market Cap$2.8B
Price Performance
Historical data including institutional events
Loading price data...
Company Profile
R
Ryan Watts
CEO & Executive Director
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinsonâs and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The companyâs OTV programs also comprise DNL628 targeting tau for Alzheimerâs disease; and DNL422 targeting alpha synuclein for Parkinsonâs disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimerâs disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
- Founded
Loading company sections...